BGB-16673

N/A

Report date: 2026/04/14 20:00:15
NME

Base Information

Drug NameBGB-16673
Drug Alias NameBGB-16673BGB-1663
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionTyrosine-protein kinase BTK degraders
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsRichter's SyndromeChronic UrticariaHematologic Diseases +[13
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[30
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Inactive CompaniesN/A
Active IndicationsRichter's SyndromeChronic UrticariaHematologic Diseases +[12
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A